<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881488</url>
  </required_header>
  <id_info>
    <org_study_id>CTX-471-001</org_study_id>
    <nct_id>NCT03881488</nct_id>
  </id_info>
  <brief_title>Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies</brief_title>
  <official_title>A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients With Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Compass Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Iqvia Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Compass Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, first-in-human study of CTX-471 monotherapy in patients with&#xD;
      metastatic or locally advanced malignancies that have progressed while receiving an approved&#xD;
      PD-1 or PD-L1 inhibitor. The study will be conducted in 2 parts: Part 1 Dose Escalation and&#xD;
      Part 2 Dose Expansion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2019</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose(s) of CTX 471 to be examined in Part 2 and the recommended Phase 2 dose(s)</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of CTX-471</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the serum concentrations of CTX-471 versus time curve (AUC)</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2) of serum concentrations of CTX-471</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of anti-drug antibodies (ADAs) and/or neutralizing antibodies of CTX-471</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until 60 days after the last CTX-471 injection (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (Percentage of Participants With Objective Response) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Baseline until confirmed disease progression (CR or PR) (up to 2 years)</time_frame>
    <description>ORR will be calculated as the number of participants with a confirmed complete response (CR) or a partial response (PR) divided by the number of participants dosed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>From the date of first confirmed CR or PR until the first date of recurrent or progressive disease (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until disease progression or death, whichever occur first (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From first dose of CTX-471 (Week 1 Day 1) until death (up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Locally Advanced Solid Tumor</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of CTX-471 depending on cohort at enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two dose groups of CTX-471 (0.3 mg/kg and 0.6 mg/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTX-471</intervention_name>
    <description>IV infusion every 2 weeks</description>
    <arm_group_label>Part 1 Dose Escalation</arm_group_label>
    <arm_group_label>Part 2 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Histologically confirmed diagnosis of metastatic or locally advanced malignancies&#xD;
&#xD;
          3. Measurable disease per RECIST 1.1&#xD;
&#xD;
          4. Disease progression after at least 12 weeks and at least 2 doses of a commercially&#xD;
             available PD-1 or PD-L1 inhibitor per approved prescriber's information, whether&#xD;
             monotherapy or in combination therapy, with no other intervening systemic anticancer&#xD;
             therapy prior to enrollment&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          6. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          7. Adequate bone marrow function defined by ANC of ≥ 1.5×10^9/L, platelet count of&#xD;
             ≥100.0×10^9/L, and hemoglobin of ≥ 9.0 g/dL (with or without transfusion)&#xD;
&#xD;
          8. Adequate hepatic function defined as serum total bilirubin &lt; 2 mg/dL, AST/ALT ≤ 2.5 ×&#xD;
             ULN (or ≤ 5 × ULN in patients with liver metastases)&#xD;
&#xD;
          9. Adequate renal function defined as serum creatinine &lt; 1.5 × ULN or with normal serum&#xD;
             creatinine levels defined as creatinine clearance &gt; 60 mL/min as determined by the&#xD;
             Cockcroft-Gault equation&#xD;
&#xD;
         10. Female patients must be surgically sterile (or have a monogamous partner who is&#xD;
             surgically sterile) or be least 2 years postmenopausal or commits to use 2 acceptable&#xD;
             forms of birth control (defined as the use of an intrauterine device, a barrier method&#xD;
             with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the&#xD;
             duration of the study and for 4 months following the last dose of study treatment.&#xD;
             Male patients must be sterile (biologically or surgically) or commit to the use of a&#xD;
             reliable method of birth control (condoms with spermicide) for the duration of the&#xD;
             study and for 4 months following the last dose of study treatment&#xD;
&#xD;
         11. Female patients who are women of childbearing potential (WCBP) must have a negative&#xD;
             serum pregnancy test at Screening within 7 days of dosing with CTX-471&#xD;
&#xD;
         12. Last dose of previous PD-1 or PD-L1 therapy ≥ 28 days, other anticancer therapy &gt; 21&#xD;
             days (or 2 half-lives for proteins, whichever is longer), radiotherapy &gt; 21 days&#xD;
             (concurrent localized palliative radiotherapy is allowed during CTX-471 treatment), or&#xD;
             surgical intervention &gt;21 days prior to the first dose of CTX-471&#xD;
&#xD;
         13. Resolution of all prior anti-cancer therapy toxicities ≤ Grade 1&#xD;
&#xD;
         14. Willingness to provide pre- and post-treatment fresh tumor biopsies&#xD;
&#xD;
         15. Capable of understanding and complying with protocol requirements&#xD;
&#xD;
         16. Signed and dated institutional review board/independent ethics committee-approved&#xD;
             informed consent form before any protocol-directed screening procedures are performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Developed clinically significant adverse reaction to PD-1 or PD-L1 therapy, including&#xD;
             immune related adverse reactions, which led to discontinuation of treatment&#xD;
&#xD;
          2. Prior treatment with other investigational immune-oncology therapies&#xD;
&#xD;
          3. Systemic therapy with immunosuppressive agents within 7 days before the start of&#xD;
             CTX-471 treatment. Topical, intranasal, intraocular, or inhaled corticosteroids and&#xD;
             physiologic replacement for patients with adrenal insufficiency are allowed&#xD;
&#xD;
          4. Patient is a pregnant or lactating WCBP&#xD;
&#xD;
          5. Prior organ transplantation&#xD;
&#xD;
          6. Active hepatitis B virus, hepatitis C virus, or human immunodeficiency virus infection&#xD;
             or a positive serological test at Screening within 28 days of dosing with CTX 471&#xD;
&#xD;
          7. Active autoimmune disease or medical conditions requiring chronic steroid (ie, &gt; 10&#xD;
             mg/day prednisone or equivalent) or immunosuppressive therapy. Patients with a prior&#xD;
             history of autoimmune disease may be eligible following discussion with the Medical&#xD;
             Monitor&#xD;
&#xD;
          8. History of central nervous system metastases&#xD;
&#xD;
          9. History of seizure disorders&#xD;
&#xD;
         10. Congestive heart failure (&gt; New York Heart Association Class II), active coronary&#xD;
             artery disease, unevaluated new onset angina within 3 months or unstable angina&#xD;
             (angina symptoms at rest) or clinically significant cardiac arrhythmias&#xD;
&#xD;
         11. Other systemic conditions or organ abnormalities that in the opinion of the&#xD;
             Investigator may interfere with the conduct and/or interpretation of the current study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Scheutz, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Compass Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Bossi</last_name>
    <phone>617-500-8099</phone>
    <phone_ext>118</phone_ext>
    <email>jill.bossi@compasstherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ocala Oncology Center</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ketan Doshi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates Of The Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seth Rosen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanner Johanns, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mt Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Galsky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University School of Medicine</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Choe, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute for Translational Oncology Research (ITOR)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W. Jeffrey Edenfield, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minal Barve, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

